• Contact Us
  • Sign Up
  • TWITTER
Microbiome Times Magazine

Drug Database Powered by:

  • Human Health
  • Animal Health
  • Phytobiome
  • Finance
    • Finance Articles
    • Microbiome Stocks
  • Drug Database
    • About
    • Login/ Register
  • Issue Archive
  • Advertise

Month: August 2020

Pharma & Human Health

Group of international scientists align on a definition for ‘synbiotic’

August 28, 2020 Staff Editor

The word ‘synbiotic’ appears on a growing number of food and supplement products, with synbiotic ingredients showing promise for modulating the community of microbes living in the human gut, while providing a health benefit. Synbiotics […]

Finance

Seres Therapeutics Announces Closing of Public Offerings of 12,075,000 Shares of Common Stock

August 26, 2020 Staff Editor

Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres”), a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease, today […]

Finance

Micronoma Launches with $3 Million Seed Funding

August 19, 2020 Staff Editor

Micronoma, an early cancer-detection biotech that seeks to develop and commercialize a minimally invasive, microbiome-based method, announced today that it has closed a $3 million seed financing round led by microbiome-focused investor, SymBiosis, LLC. The […]

Finance

Scioto Biosciences Receives Series B Investment from Genome & Company

August 13, 2020 Staff Editor

Scioto Biosciences announced today the closing of a strategic investment of up to $26.5M from Genome & Company and other investors to join in an upcoming tranche. Genome & Company is a leading microbiome company […]

Editor's Choice

Seres Therapeutics Announces Positive Topline Results from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. difficile Infection

August 10, 2020 Staff Editor

Seres Therapeutics, Inc. (Nasdaq: MCRB) today reported positive topline results from the pivotal Phase 3 ECOSPOR III study evaluating its investigational oral microbiome therapeutic SER-109 for recurrent C. difficile infection (CDI). The study showed that […]

Editor's Choice

The integral role of the microbiome in a post-pandemic world

August 10, 2020 Isabelle de Cremoux

At the beginning of 2020, I said to the Seventure team, that this would be the ‘Year of the Microbiome’.I still believe this will be true even in a COVID-19 world when our lives have […]

Microbiome-based Diagnostics & Biomarkers: Free Market Report

Sign Up to Free Newsletter

The Microbiome Drug Database

Advertisments

The Microbiome Drug Landscape report: Promising clinical performance and signs of a maturing industry

Market Reports
October 26, 2020
Abstract Year 2020 has been a pivotal year for microbiome-focused drug companies. This year the industry saw the release of two much-anticipated Phase 3 studies, which showed positive results and set the stage for new [...]

Editor’s Choice

  • Fecal transplant turns cancer immunotherapy non-responders into responders
    February 10, 2021
  • Why microbiota samples should be collected in all clinical trials?
    January 26, 2021
  • Kaleido Biosciences Announces Positive Interim Results of Controlled Study of KB109 in Patients with Mild-to-Moderate COVID-19
    January 20, 2021
  • Poor gut health connected to severe COVID-19, new review shows
    January 18, 2021
  • First Published Clinical Trial Using Live Biotherapeutic Candidate In COVID-19 Patients Suggests Role In Improving Outcomes
    September 25, 2020

ACCESS THE DECEMBER 2020 ISSUE:

Categories
  • Animal Health
  • Editor's Choice
  • Finance
  • Lallemand Health Solutions
  • Market Reports
  • Pharma & Human Health
  • Phytobiome & Environment
  • Premium Content
  • Reports
  • Sponsored Content
  • Uncategorized
  • Video
  • Webinar
sign up

Sign up to the Microbiome Times newsletter